Unaudited interim results for the three-and nine-month periods ended 30 September 2024
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma - December 8, 2024
- Slate360 Provides Valuable Insights on the Advantages of Working with a Skilled Healthcare Event Marketing Agency - December 8, 2024
- Global Aerospace’s SM4 Aviation Safety Program Provides Actionable Advice for Enhancing Safety in Your Flight Department - December 8, 2024